Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$6.75 USD
+0.54 (8.70%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.74 -0.01 (-0.15%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Werewolf Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 20 | 16 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 20 | 16 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 60 | 72 | 50 | 22 | 10 |
Income After Depreciation & Amortization | -41 | -56 | -50 | -22 | -10 |
Non-Operating Income | 6 | 2 | 0 | 7 | 0 |
Interest Expense | 3 | 0 | 0 | 0 | 0 |
Pretax Income | -37 | -54 | -50 | -15 | -10 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -37 | -54 | -50 | -15 | -10 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -37 | -54 | -50 | -15 | -10 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -39 | -55 | -50 | -22 | -10 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -41 | -56 | -50 | -22 | -10 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 35.65 | 28.86 | 18.46 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.05 | -1.86 | -10.94 | NA | NA |
Diluted Net EPS (GAAP) | -1.05 | -1.86 | -10.94 | -28.09 | NA |
Fiscal Year end for Werewolf Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 1.50 | 5.90 | 8.08 | 4.46 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 1.50 | 5.90 | 8.08 | 4.46 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 14.46 | 15.15 | 14.15 | 16.69 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -12.96 | -9.25 | -6.07 | -12.23 |
Non-Operating Income | NA | 4.10 | 0.97 | 0.97 | 0.24 |
Interest Expense | NA | 3.14 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -12.00 | -8.29 | -5.10 | -11.98 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -12.00 | -8.29 | -5.10 | -11.98 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -12.00 | -8.29 | -5.10 | -11.98 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 36.57 | 35.65 | 35.56 | 34.79 |
Diluted EPS Before Non-Recurring Items | NA | -0.33 | -0.23 | -0.14 | -0.34 |
Diluted Net EPS (GAAP) | NA | -0.34 | -0.23 | -0.14 | -0.34 |